Navigation Links
Study paves way to design drugs aimed at multiple protein targets at once
Date:12/12/2012

CHAPEL HILL, N.C. An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

This accomplishment, described in the Dec. 13, 2012 issue of the journal Nature, may prove invaluable for developing drugs to treat many common human diseases such as diabetes, high blood pressure, obesity, cancer, schizophrenia, and bi-polar disorder.

These disorders are called complex diseases because each have a number of genetic and non-genetic influences that determine susceptibility, i.e., whether someone will get the disease or not.

"In terms of the genetics of schizophrenia we know there are likely hundreds of different genes that can influence the risk for disease and, because of that, there's likely no single gene and no one drug target that will be useful for treating it, like other common complex diseases," said study co-leader, Brian L. Roth, MD, PhD, Michael J. Hooker Distinguished Professor of Pharmacology in the UNC School of Medicine, professor in the Division of Chemical Biology and Medicinal Chemistry in the UNC Eshelman School of Pharmacy, and director of the National Institute of Mental Health Psychoactive Drug Screening Program.

In complex neuropsychiatric conditions, infectious diseases and cancer, Roth points out that for the past 20 years drug design has been selectively aimed at a single molecular target, but because these are complex diseases, the drugs are often ineffective and thus many never reach the market.

Moreover, a drug that acts on a single targeted protein may interact with many other proteins. These undesired interactions frequently cause toxicity and adverse effects.

"And so the realization has been that perhaps one way forward is to make drugs that hit collections of drug targets simultaneously. This paper provides a way to do that," Roth said.

The new way involves automated drug design by computer that takes advantage of large databases of drug-target interactions. The latter have been made public through Roth's lab at UNC and through other resources.

Basically, the researchers, also co-led by Andrew L. Hopkins, PhD in the Division of Biological Chemistry and Drug Discovery, College of Life Sciences, at the University of Dundee, in Scotland, used the power of computational chemistry to design drug compounds that were then synthesized by chemists, tested in experimental assays and validated in mouse models of human disease.

The study team experimentally tested 800 drug-target predictions of the computationally designed compounds; of these, 75 percent were confirmed in test-tube (in vitro) experiments.

Drug to target engagement also was confirmed in animal models of human disease. In a mouse model of attention deficit hyperactivity disorder (ADHD), mice missing a particular dopamine receptor engage in recurrent aberrant behaviors similar to what is seen in ADHD: distractibility and novelty seeking. "We created a compound that was predicted to prevent those recurrent behaviors and it worked quite well," Roth said.

The researchers then tested the compound in another mouse model where a particular enzyme for a brain neuropeptide is missing. Distractibility and novelty seeking also are behavioral features in these animals. And the drug had the same effect in those mice.

The new drug design process includes ensuring that compounds enter the brain by crossing the blood-brain barrier. These, too, were tested successfully in live animals.

According to Roth, pharmaceutical company chemists had suggested that the objective of a drug hitting multiple targets simultaneously is impossible and unlikely to succeed. "Here we show how to efficiently and effectively make designer drugs that can do that."


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina Health Care
Source:Eurekalert  

Related medicine news :

1. Targeted micro-bubbles detect artery inflammation, MU study finds
2. Study Finds New SARS-Like Virus Spread Through Bats, Pigs
3. Junk Food Taxes Pay Off, Study Finds
4. Brain Changes Continue After Childs Concussion: Study
5. Even Light Smoking Boosts Womens Risk of Sudden Heart Death: Study
6. Primary Care Doctors Meet Needs of Diabetics, Study Says
7. Avastin Shows No Benefit for Earlier Colon Cancer: Study
8. Regular Exercise May Add Years to Life, Study Finds
9. Coffee May Lower Risk of Death From Mouth Cancer: Study
10. RSNA: New Study Finds Brain Angioplasty and Stents Safe and Effective for Stroke Patients
11. Salmonella spreads by targeting cells in our gut, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study paves way to design drugs aimed at multiple protein targets at once
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... of the Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition ... in America,” a live webinar designed to help nutrition educators and students inform ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC TITLE ... the official title sponsor of the Baltimore Women’s Classic, the largest all women’s 5K ... walk or run the course around the Baltimore Inner Harbor. Mercy has been the ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Orthopedic Navigation Systems Market 2014 - 2025" report to ... ... to reach USD 303.7 million by 2025. Increasing geriatric population ... the demand for orthopedic navigation systems over the forecast period. ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
(Date:3/29/2017)... York , March 29, 2017 ... published a report, which provides an exhaustive study ... the study, nearly 242 companies are functional in ... and competitive. With the leading companies, such as ... Pharma LP, focusing aggressively on various marketing strategies ...
Breaking Medicine Technology: